Literature DB >> 10569776

Cytokine control of the granulomatous response in Schistosoma mansoni-infected baboons: role of exposure and treatment.

P W Mola1, I O Farah, T M Kariuki, M Nyindo, R E Blanton, C L King.   

Abstract

Variations in exposure and treatment may contribute to heterogeneity in immunity and granuloma-induced pathology in human schistosomiasis. To examine this hypothesis, olive baboons were either repeatedly infected with Schistosoma mansoni cercariae or received an equivalent dose in a single infection. They were then cured with praziquantel and reinfected with a single exposure. Serial liver biopsies were obtained throughout the course of the experiment, and cytokine responses by peripheral blood mononuclear cells were measured every 2 to 3 weeks. Reinfection after treatment resulted in a twofold-smaller granuloma size at 6 and 9 weeks after infection compared to the size for the same period after primary infection (P < 0.001) but had no effect at 16 or 19 weeks postinfection. The pattern of exposure did not influence granuloma size. During primary infection schistosome-soluble egg antigen (SEA)-induced cytokine production correlated with granulomatous inflammation. Cytokine levels peaked during the acute infection, declined with chronic infection, and became undetectable after treatment. Reinfection after treatment stimulated a two- to three-fold increase in SEA-specific interleukin-4 (IL-4), IL-5, IL-10, IL-2, and transforming growth factor beta (TGF-beta) production and a marked rise in SEA-specific immunoglobulin E (IgE) and IgG regardless of the type of exposure. Cytokine production was significantly greater in repeatedly exposed animals (P < 0.001). SEA-induced gamma interferon production, however, did not increase with reinfection after treatment. SEA-induced TGF-beta was the only cytokine that remained elevated as the infection become chronic and correlated with diminished hepatic granuloma size, implying its participation in down-modulation. These studies demonstrate that baboons partially retain their ability to down-modulate the granulomatous response after treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10569776      PMCID: PMC97068          DOI: 10.1128/IAI.67.12.6565-6571.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  47 in total

1.  Schistosoma mansoni induces in the Kenyan baboon a novel intestinal pathology that is manifestly modulated by an irradiated cercarial vaccine.

Authors:  I O Farah; M Nyindo
Journal:  J Parasitol       Date:  1996-08       Impact factor: 1.276

2.  Schistosomiasis japonica in the Philippines: the long-term impact of population-based chemotherapy on infection, transmission, and morbidity.

Authors:  R M Olveda; B L Daniel; B D Ramirez; G D Aligui; L P Acosta; P Fevidal; E Tiu; F de Veyra; P A Peters; R Romulo; E Domingo; P M Wiest; G R Olds
Journal:  J Infect Dis       Date:  1996-07       Impact factor: 5.226

3.  Effect of praziquantel on certain immune responses of schistosomal Egyptian patients. I. Changes of specific immunoglobulins.

Authors:  Z A Shaker; H I Hassanein; M M Kamel; N M el-Bahairy; A H el-Kalouby; E H el-Raziky
Journal:  Parasitol Res       Date:  1987       Impact factor: 2.289

4.  The intensity of experimental schistosome infections modulates hepatic pathology.

Authors:  A W Cheever
Journal:  Am J Trop Med Hyg       Date:  1986-01       Impact factor: 2.345

5.  Antischistosome IgG4 and IgE responses are affected differentially by chemotherapy in children versus adults.

Authors:  J L Grogan; P G Kremsner; G J van Dam; W Metzger; B Mordmüller; A M Deelder; M Yazdanbakhsh
Journal:  J Infect Dis       Date:  1996-05       Impact factor: 5.226

6.  Release of interleukin 2 and gamma interferon by peripheral mononuclear cells in human Schistosoma mansoni infection normalizes after chemotherapy.

Authors:  K Zwingenberger; E Irschick; J G Siqueira Vergetti; A R Correia Dacal; R Janssen-Rosseck; U Bienzle; C Huber; H Feldmeier
Journal:  Scand J Immunol       Date:  1989-10       Impact factor: 3.487

7.  Cytokine control of parasite-specific anergy in human urinary schistosomiasis. IL-10 modulates lymphocyte reactivity.

Authors:  C L King; A Medhat; I Malhotra; M Nafeh; A Helmy; J Khaudary; S Ibrahim; M El-Sherbiny; S Zaky; R J Stupi; K Brustoski; M Shehata; M T Shata
Journal:  J Immunol       Date:  1996-06-15       Impact factor: 5.422

8.  Elevated proliferation and interleukin-4 release from CD4+ cells after chemotherapy in human Schistosoma haematobium infection.

Authors:  J L Grogan; P G Kremsner; A M Deelder; M Yazdanbakhsh
Journal:  Eur J Immunol       Date:  1996-06       Impact factor: 5.532

9.  IL-4 influences IL-2 production and granulomatous inflammation in murine schistosomiasis mansoni.

Authors:  T Yamashita; D L Boros
Journal:  J Immunol       Date:  1992-12-01       Impact factor: 5.422

10.  Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni.

Authors:  E J Pearce; P Caspar; J M Grzych; F A Lewis; A Sher
Journal:  J Exp Med       Date:  1991-01-01       Impact factor: 14.307

View more
  15 in total

1.  Morbidity and immune response to natural schistosomiasis in baboons ( Papio anubis).

Authors:  Idle Farah; Andreas Börjesson; Thomas Kariuki; Dorcas Yole; Mbaruk Suleman; Jann Hau; Hans-Erik Carlsson
Journal:  Parasitol Res       Date:  2003-09-18       Impact factor: 2.289

Review 2.  Regulation of granulomatous inflammation in experimental models of schistosomiasis.

Authors:  Abram B Stavitsky
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

3.  Parameters of the attenuated schistosome vaccine evaluated in the olive baboon.

Authors:  Thomas M Kariuki; Idle O Farah; Dorcas S Yole; Jason M Mwenda; Govert J Van Dam; André M Deelder; R Alan Wilson; Patricia S Coulson
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

4.  Expression of TGF-beta-like molecules in the life cycle of Schistosoma japonicum.

Authors:  M Hirata; K Hirata; T Hara; M Kawabuchi; T Fukuma
Journal:  Parasitol Res       Date:  2005-02-12       Impact factor: 2.289

5.  OspE-related, OspF-related, and Elp lipoproteins are immunogenic in baboons experimentally infected with Borrelia burgdorferi and in human lyme disease patients.

Authors:  P Scott Hefty; Chad S Brooks; Amy M Jett; Gary L White; Stephen K Wikel; Ronald C Kennedy; Darrin R Akins
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

6.  Schistosoma haematobium cercarial infection alters subsequent systemic immune responses to eggs but has minimal impact on immune responses to egg injection of the bladder.

Authors:  Le Loc; Evaristus C Mbanefo; George Khludenev; Olivia Lamanna; Nirad Banskota; Michael H Hsieh
Journal:  Parasite Immunol       Date:  2018-12-03       Impact factor: 2.280

7.  Characterization of the Histoplasma capsulatum-induced granuloma.

Authors:  Erika Heninger; Laura H Hogan; Jozsef Karman; Sinarack Macvilay; Bjork Hill; Jon P Woods; Matyas Sandor
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

Review 8.  Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Effect of chemotherapy with praziquantel on the production of cytokines and morbidity associated with schistosomiasis mansoni.

Authors:  P Martins-Leite; G Gazzinelli; L F Alves-Oliveira; A Gazzinelli; L C C Malaquias; R Correa-Oliveira; A Teixeira-Carvalho; A M S Silveira
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

10.  Experimental murine fascioliasis derives early immune suppression with increased levels of TGF-β and IL-4.

Authors:  Joon-Yong Chung; Young-An Bae; Doo-Hee Yun; Hyun-Jong Yang; Yoon Kong
Journal:  Korean J Parasitol       Date:  2012-11-26       Impact factor: 1.341

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.